FDA approves Stivarga (regorafenib) for GIST

The FDA today announced the approval of Stivarga (regorafenib) for GIST. 

“Stivarga is the third drug approved by the FDA to treat gastrointestinal stromal tumors,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It provides an important new treatment option for patients with GIST in which other approved drugs are no longer effective.”

You can read the fill press release at the link below:

FDA approves Stivarga for advanced gastrointestinal stromal tumors

Regorafenib Phase 3 Trial Report Abstract

The abstract of the report on the phase 3 trial of Regorafenib in GIST is now available online at  PubMed.  The original full report was published in the British journal 'Lancet' on January 26, 2013.  You can read the abstract by clicking the link below:

"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial."

News: Antibody hinders resistant GIST in lab

If you check this web page on a regular basis you will see news about GIST in the right-hand menu.  Yesterday there was news about a press release from Stanford University in California.  Life Raft Group Research team members Matt van de Rijn and Jonathan Fletcher have co-authored a paper about a new approach to fighting resistant GIST in the lab.  You can read the press release by clicking the title below:

Antibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab tests, researchers say

You can read the associated news articles by clicking on the titles that include 'antibody' in the "GIST IN GOOGLE NEWS" or by clicking these saved links below:

Science Daily

Medical.net News

Scope blog @ Stanford Univ.